Rexlemestrocel-L Phase 3 Trial Results in Chronic Heart

NEW YORK, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory...

Related Keywords

China ,Australia ,Japan ,United States ,Baylor College Of Medicine ,Texas ,Singapore ,Australian ,American ,Kristen Bothwell ,Paul Hughes ,Emerson Perin ,Texas Heart Institute ,American Heart Association ,Linkedin ,York Heart Association ,Twitter ,Australian Securities Exchange ,Mesoblast Limited Nasdaq ,Corporate Communications Investors ,European Society Of Cardiology ,Journal Of The American Heart Association ,New York Heart Association ,Heart Failure ,Medical Director ,Clinical Professor ,Baylor College ,Randomized Trial ,Targeted Transendocardial Delivery ,Mesenchymal Precursor Cells ,High Risk Chronic Heart Failure Patients ,Reduced Ejection ,Breaking Science ,Mesoblast Limited ,Private Securities Litigation Reform Act ,Australian Stock Exchange Msb Ax ,